Delivery of S1P receptor-targeted drugs via biodegradable polymer scaffolds enhances bone regeneration in a critical size cranial defect

Journal of Biomedical Materials Research - Part A

Volumn 102, Issue 4, 2014, Pages 1210-1218

  Das, Anusuya ^a,b   Tanner, Shaun ^b   Barker, Daniel A ^c   Green, David ^d   Botchwey, Edward A ^e  

^a UNIVERSITY OF VIRGINIA   (United States)

^b University of Virginia   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d University of Virginia   (United States)

^e GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

biodegradable polymer scaffolds; bone tissue engineering; drug delivery

Indexed keywords

BONE; COMPUTERIZED TOMOGRAPHY; DEFECTS; DRUG DELIVERY; MICROSPHERES;

BIODEGRADABLE POLYMER SCAFFOLDS; BONE REGENERATION; BONE TISSUE ENGINEERING; MICROCOMPUTED TOMOGRAPHY; POLY LACTIC-CO-GLYCOLIC ACID; SPHINGOSINE 1 PHOSPHATES; SURFACE LOCALIZATION; TEMPORAL AND SPATIAL;

SCAFFOLDS (BIOLOGY);

FINGOLIMOD; MICROSPHERE; POLYGLACTIN; POLYMER; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIODEGRADATION; BONE MASS; BONE REGENERATION; BONE REMODELING; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; HISTOLOGY; HYDROPHOBICITY; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; OSSIFICATION; RAT; SKULL DEFECT;

BIODEGRADABLE POLYMER SCAFFOLDS; BONE TISSUE ENGINEERING; DRUG DELIVERY;

ANIMALS; BONE REGENERATION; DRUG DELIVERY SYSTEMS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LACTIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICROSPHERES; OSTEOGENESIS; POLYGLYCOLIC ACID; PROPYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LYSOSPHINGOLIPID; SKULL; SPHINGOSINE; TIME FACTORS; TISSUE SCAFFOLDS;

EID: 84894426422     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34779     Document Type: Article

References (29)

1. Amini AR, Laurencin CT, Nukavarapu SP,. Bone tissue engineering: recent advances and challenges. Crit Rev Biomed Eng 2012; 40: 363-408.
2. Woo EJ,. Adverse events after recombinant human BMP2 in nonspinal orthopaedic procedures. Clin Orthop Relat Res 2013; 47: 1701-1711.
3. Woo EJ,. Recombinant human bone morphogenetic protein-2: Adverse events reported to the manufacturer and user facility device experience database. Spine J 2012; 12: 894-899.
4. Chen RR, Silva EA, Yuen WW, Brock AA, Fischbach C, Lin AS, Guldberg RE, Mooney DJ,. Integrated approach to designing growth factor delivery systems. FASEBJ 2007; 21: 3896-3903.
5. Lynch KR, Macdonald TL,. Spingosine 1-phosphate chemical biology. Biochim Biophys Acta 2008; 1781: 508-512.
6. Hla T,. Signaling and biological actions of sphingosine 1-phosphate. Pharmacol Res 2003; 47: 401-407.
7. Mandala S, Hajdu R, Bergstrom J, Quackenbush, E, Xie, J, Milligan, J, Thornton R, Shei G-J, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W, Rosen H,. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science (New York) 2002; 296: 346-349.
8. Sefcik LS, Petrie Aronin CE, Awojoodu AO, Shin SJ, Gabhann FM, Macdonald TL, Wamhoff BR, Lynch KR, Peirce SM, Botchwey EA,. Selective activation of sphingosine 1-phosphate receptors 1 and 3 promotes local microvascular network growth. Tissue Eng A 2011; 17: 617-629.
9. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ,. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphinhosine-1-phosphate. Proc Natl Acad Sci USA 2008; 105: 20764-20769.
10. Petrie Aronin CE, Sefcik LS, Tholpady SS, Tholpady A, Sadik KW, Macdonald TL, Peirce SM, Wamhoff BR, Lynch KR, Ogle RC, Botchwey EA,. FTY720 promotes local microvascular betwork formation and regeneration of cranial bone defects. Tissue Eng A 2010; 16: 1801-1809.
11. Zhu, R, Snyder AH, Kharel Y, Schaffter L, Sun Q, Kennedy PC, Lynch KR, Macdonald TL,. Asymmetric synthesis of conformationally constrained fingolimod analogues-discovery of an orally active sphingosine 1-phosphate receptor type-1 agonist and receptor type-3 antagonist. J Med Chem 2007; 50: 6428-6435.
12. Brinkmann V, Lynch KR,. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 2002; 14: 569-575.
13. Berkland C, Kim KK, Pack DW,. PLG microsphere size controls drug release rate through several competing factors. Pharm Res 2003; 20.
14. Choi Y-S, Joo J-R, Hong A, Park J-S,. Development of drug-loaded PLGA microparticles with different release patterns for prolonged drug delivery. Bull Korean Chem Soc 2011; 32: 867-872.
15. Mollica F, Biondi M, Muzzi S, Ungaro F, Quaglia F, Rotonda MI, La Netti PA,. Mathematical modeling of the evolution of protein distribution within single PLGA microspheres: Prediction of local concentration profiles and release kinetics. J Mater Sci Mater Med 2008; 19: 1587-1593.
16. Tran V-T, Benoît J-P, Venier-Julienne M-C,. Why and how to prepare biodegradable, monodispersed, polymeric microparticles in the field of pharmacy [J]. Int J Pharm 2011; 407: 1-11.
17. Alexis F,. Factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly[(lactic acid)-co-(glycolic acid)]. Polym Int 2005; 54: 36-46.
18. Bezemer JM, Radersma R, Grijpma DW, Dijkstra PJ, van Blitterswijk CA, Feijen J,. Microspheres for protein delivery prepared from amphiphilic multiblock copolymers 2. Modulation of release rate. J Control Release 2000; 67: 249-260.
19. Sefcik LS, Petrie Aronin CE, Wieghaus KA, Botchwey E,. Sustained release of sphingosine 1-phosphate for therapeutic arteriogenesis and bone tissue engineering. Biomaterials 2008; 29: 2869-2877.
20. Chen RR, Silva EA, Yuen WW, Mooney DJ,. Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm Res 2007; 24: 258-264.
21. Freeman I, Cohen S,. The influence of the sequential delivery of angiogenic factors from affinity-binding alginate scaffolds on vascularization. Biomaterials 2009; 30: 2122-2131.
22. Berkland C, Kipper MJ, Narasimhan B, Kim K, Pack DW,. Microspheres size, precipitation kinetics and drug distribution controld rug release from biodegradable polyanhydride microspheres. J Control Release 2004; 94: 129-141.
23. Lin C-C, Anseth KS,. PEG hydrogels for the controlled release of biomolecules in regenerative medicine. Pharm Res 2009; 26: 631-643.
24. Singh M, Morris CP, Ellis RJ, Detamore MS, Berkland C,. Microsphere-based seamless scaffolds containing macroscopic gradients of encapsulated factors for tissue engineering. Tissue Eng Part C Methods 2008; 14: 299-309.
25. Alford SK, Kaneda MM, Wacker BK, Elbert DL,. Endothelial cell migration in human plasma is enhanced by a narrow range of added sphingosine 1-phosphate: Implications for biomaterials design. J Biomed Mater Res A 2009; 88: 205-212.
26. Sanchez T, Estrada-Hernandez T, Paik J-H, Wu M-T, Venkataraman K, Brinkmann V, Claffey K, Hla T,. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 2003; 278: 47281-47290.
27. Maeda Y, Matsuyuki H, Shimano K, Kataoka H, Sugahara K, Chiba K, Alerts E,. Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3. J Immunol 2007; 178: 3437-3446.
28. Ryser MF, Ugarte F, Lehmann R, Bornh€auser M, Brenner S,. S1P(1) overexpression stimulates S1P-dependent chemotaxis of human CD34+ hematopoietic progenitor cells but strongly inhibits SDF-1/CDCR4-dependent migration and in vivo homing. Mol Immunol 2008:46: 166-171.
29. Ishii M, Kikuta J, Shimazu Y, Meier-Schellersheim M, Germain RN,. Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo. J Exp Med 2010; 207: 2793-2798